July 17, 2014 – The U.S. Food and Drug Administration (FDA) recently approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). Hereditary angioedema, which is caused …

FDA approves the new product Ruconest (recombinant C1-Esterase inhibitor) to treat the rare genetic disease by the name of hereditary angioedema (HAE) Read more »

May 15, 2014 –  The U.S. Food and Drug Administration recently approved Zontivity (vorapaxar) tablets to reduce the risk of heart attack, stroke, cardiovascular death, and need for procedures to restore the blood flow to the heart in patients with a …

FDA approved Vorapaxar [Zontivity] to reduce the risk of stroke and heart attacks in high-risk patients Read more »